Literature DB >> 11682321

Lung cancer--a philosophical, ethical, and personal perspective.

F J Brescia1.   

Abstract

Lung cancer is a formidable worldwide health problem causing more deaths than breast, prostate, and colorectal cancer combined. Eighty percent are non-small cell type (NSCLC) and less than one in five patients can have a curative resection. Decisionmaking in treating cancer, and lung cancer specifically, requires an understanding of the basic ethical principles as well as a prioritization of values beyond medical knowledge alone. Choosing a treatment plan can be difficult because of the multiple confronting dilemmas occurring simultaneously. Economic analysis also is required of every major treatment strategy proposed. Active patient involvement is helpful in making these important and difficult choices at the same time clinicians must be mindful of their roles as healers, educators, and innovators of knowledge in a disease that has a five year mortality rate of nearly 90%. Finally, because end of life care issues are so common with this illness, clinicians must be aware of their importance in making dying easier for so many individuals.

Entities:  

Mesh:

Year:  2001        PMID: 11682321     DOI: 10.1016/s1040-8428(01)00140-8

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  3 in total

1.  [Instruction in medical ethics during clinical training for medical students: report on experience in radio-oncology].

Authors:  C Schäfer; C Lenk; O Kölbl
Journal:  Radiologe       Date:  2006-12       Impact factor: 0.635

2.  TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells.

Authors:  Agnieszka Checinska; Giuseppe Giaccone; Bas S J Hoogeland; Carlos G Ferreira; Jose A Rodriguez; Frank A E Kruyt
Journal:  BMC Cancer       Date:  2006-06-23       Impact factor: 4.430

3.  The attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative study.

Authors:  Nir Lipsman; Abby Skanda; Jonathan Kimmelman; Mark Bernstein
Journal:  BMC Palliat Care       Date:  2007-11-08       Impact factor: 3.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.